Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Advanced age, poor left ventricular function, and congestive heart failure are known predictors of atrial fibrillation (AF) in acute myocardial infarction (AMI) patients. Recent advances in AMI treatment may have changed the occurrence of new-onset AF. Thus, we investigated the factors associated with the development of new-onset AF in ST elevation myocardial infarction (STEMI) patients.

Methods: This study included 527 STEMI patients [mean age, 60.6±12.8 years; 102 (19.4%) women] who underwent primary percutaneous coronary intervention (PCI) in the previous 7 years. New-onset AF was evaluated following STEMI treated by primary PCI. Patients who developed AF during this follow-up period were compared with those who did not develop AF to identify factors that were associated with the development of AF.

Results: New-onset AF was documented in 81 patients (15.4%) at 1 year after STEMI. Patients with new-onset AF (n=81) tended to be older (p<0.001); were more often female (p=0.009); had more congestive heart failure (p=0.015); had less use of beta-blockers (p=0.001); had more often used antiarrhythmic drugs (p<0.001); experienced cardiogenic shock more frequently (p=0.038); had lower left ventricular ejection fraction (p=0.024); and had higher E velocity (p<0.001), E/e' (p=0.011), and left atrial volume index (LAVI; p=0.029) than the 446 patients with no AF. Multivariate regression analysis revealed that cardiogenic shock, LAVI, and age were predictors of new-onset AF in STEMI patients (OR 2.823, 1.254, and 1.124; p=0.005, <0.001, and 0.028, respectively).

Conclusion: Cardiogenic shock was a new predictor of new-onset AF in STEMI patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jjcc.2017.08.004DOI Listing

Publication Analysis

Top Keywords

factors associated
12
associated development
12
atrial fibrillation
8
year stemi
8
stemi treated
8
treated primary
8
primary pci
8
myocardial infarction
8
stemi patients
8
stemi
5

Similar Publications

An Investigation of Hyperostosis Frontalis Interna in a Modern Anatomical Body Donor Population.

Clin Anat

September 2025

Department of Communication Disorders and Sciences, Rush University Medical Center, Chicago, Illinois, USA.

This research sought to examine the prevalence and severity of hyperostosis frontalis interna (HFI) in the Chicagoland anatomical body donor population. The study further aimed to elucidate potential demographic risk factors for HFI, including sex, age at death, and structural vulnerability index (SVI), as well as any common comorbidities, as gleaned from death certificates. HFI is an irregular bony overgrowth of the endocranial surface of the frontal bone.

View Article and Find Full Text PDF

Systematic analyses uncover plasma proteins linked to incident cardiovascular diseases.

Protein Cell

August 2025

Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200433, China.

Cardiovascular disease (CVD) research is hindered by limited comprehensive analyses of plasma proteome across disease subtypes. Here, we systematically investigated the associations between plasma proteins and cardiovascular outcomes in 53,026 UK Biobank participants over a 14-year follow-up. Association analyses identified 3,089 significant associations involving 892 unique protein analytes across 13 CVD outcomes.

View Article and Find Full Text PDF

Background And Objectives: Pollen-food allergy syndrome (PFAS) is a frequent comorbidity in individuals with hay fever. Identifying risk factors and allergen clusters can aid targeted interventions and management strategies. Objective: This study characterizes PFAS in patients with hay fever and identifies associated risk factors using the mobile health platform, AllerSearch.

View Article and Find Full Text PDF

Genetic factors associated with the co-occurrence of endometriosis with antiphospholipid syndrome (Review).

Exp Ther Med

October 2025

Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, 71003 Heraklion, Greece.

Immune-related factors may serve an important role in the development of endometriosis, considering the occurrence of substantial abnormalities in the immune system of women with endometriosis, including reduced T-cell reactivity and natural killer cell cytotoxicity, as well as increased numbers and activation of peritoneal macrophages. Moreover, women suffering from endometriosis are at a higher risk for developing various autoimmune diseases as comorbidities of endometriosis. Recent epidemiological data demonstrate that patients with endometriosis have a significantly higher risk (2.

View Article and Find Full Text PDF

When is A Kidney Biopsy Indicated During the Treatment of Brain Cancer?

Eur J Case Rep Intern Med

August 2025

Nephrology Department, Unidade Local de Saúde de Braga, Braga, Portugal.

Introduction: Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and is widely used in oncology for its anti-angiogenic properties. However, VEGF inhibition may result in significant nephrotoxicity, including thrombotic microangiopathy (TMA). While systemic TMA is well-described, isolated renal-limited TMA remains under recognised.

View Article and Find Full Text PDF